This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Daneryd, P. Articles by Lundholm, K. Search for Related Content PubMed PubMed Citation Articles by Daneryd, P. Articles by Lundholm, K.

Protection of Metabolic and Exercise Capacity in Unselected Weight-losing Cancer Patients following Treatment with Recombinant Erythropoietin: A Randomized Prospective Study¹

Department of Surgery and Clinical Nutrition, Sahlgrenska University Hospital, Göteborg University, S-413 45 Göteborg, Sweden

This study was aimed at evaluating whether anemia could be prevented in unselected weight-losing cancer patients on anti-inflammatory treatment by early and prophylactic treatment with recombinant human erythropoietin (rhEPO) and whether such a benefit could be translated into improved physical function and metabolic efficiency.

One hundred eight cancer patients who experienced progressive cachexia due to solid, mainly gastrointestinal tumors were randomized to receive twice daily a cyclo-oxygenase inhibitor (controls; indomethacin, 50 mg twice a day) or indomethacin and erythropoietin, provided on individual basis to prevent development of progressive anemia (study patients; indomethacin, 50 mg twice a day plus rhEPO; range, 12,000–30,000 units per week). All patients were treated and followed up until death or to preterminal stage. Biochemical tests (blood, liver, kidney, and thyroid), nutritional state assessment (food intake and body composition), and exercise testing with simultaneous measurements of respiratory gas exchanges before and during exercise were performed before institution of treatments and then at regular intervals during the treatment period (2–30 months after start).

Study and control patients did not differ in survival. rhEPO prevented development of anemia during the entire observation period. This was associated with a significantly more preserved maximum exercise capacity in study patients compared to control patients during the follow-up period (101 ± 10 versus 66 ± 6 W; P < 0.0001), based on more effective ventilation and whole-body respiratory gas exchanges. These improvements were also evident when exercise performance was normalized to lean body mass, an indirect measure of the skeletal muscle mass. The metabolic efficiency, expressed as oxygen uptake per watt produced, was also significantly preserved in rhEPO-treated patients compared to controls (14.1 ± 1.1 versus 16.3 ± 0.9 ml O₂/W, P < 0.05).

Our results demonstrate that institution of early and prophylactic rhEPO treatment to patients with progressive cancer prevents development of tumor-induced anemia. This achievement was associated with a better preserved exercise capacity, which is explained in part by improved whole-body metabolic and energy efficiency during work load.

¹ Supported in part by: Swedish Cancer Society Grants 2014-B96-10XCC, 2014-B93-07XDD, and 01PAA; Medical Research Council Grants K97-17X-08712-09C and K97-17X-12081-01G); the Tore Nilson Foundation; the Assar Gabrielsson Foundation (AB Volvo); the Jubileumskliniken Foundation; the IngaBritt and Arne Lundberg Research Foundation; the Axel and Margaret Ax:son Johnson Foundation; the Knut and Alice Wallenberg Foundation; the Swedish and Göteborg Medical Societies; and the Medical Faculty, University of Göteborg.

² To whom requests for reprints should be addressed, at Sahlgrenska University Hospital, Department of Surgery, SE-413 45 Göteborg, Sweden. Phone: 46-31-3422239; Fax: 46-31-826539; E-mail: Kent.Lundholm@surgery.gy.se.

Received 6/24/98. Accepted 10/ 5/98.

This article has been cited by other articles:

				K. S. Courneya, L. W. Jones, C. J. Peddle, C. M. Sellar, T. Reiman, A. A. Joy, N. Chua, L. Tkachuk, and J. R. Mackey Effects of Aerobic Exercise Training in Anemic Cancer Patients Receiving Darbepoetin Alfa: A Randomized Controlled Trial Oncologist, September 1, 2008; 13(9): 1012 - 1020. [Abstract] [Full Text] [PDF]

				M. Fouladiun, U. Korner, L. Gunnebo, P. Sixt-Ammilon, I. Bosaeus, and K. Lundholm Daily Physical-Rest Activities in Relation to Nutritional State, Metabolism, and Quality of Life in Cancer Patients with Progressive Cachexia Clin. Cancer Res., November 1, 2007; 13(21): 6379 - 6385. [Abstract] [Full Text] [PDF]

				K. Lundholm, U. Korner, L. Gunnebo, P. Sixt-Ammilon, M. Fouladiun, P. Daneryd, and I. Bosaeus Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism, and Physical Functioning Clin. Cancer Res., May 1, 2007; 13(9): 2699 - 2706. [Abstract] [Full Text] [PDF]

				T. Yavuzsen, M. P. Davis, D. Walsh, S. LeGrand, and R. Lagman Systematic Review of the Treatment of Cancer-Associated Anorexia and Weight Loss J. Clin. Oncol., November 20, 2005; 23(33): 8500 - 8511. [Abstract] [Full Text] [PDF]

				E. Lindholm, P. Daneryd, U. Korner, A. Hyltander, M. Fouladiun, and K. Lundholm Effects of Recombinant Erythropoietin in Palliative Treatment of Unselected Cancer Patients Clin. Cancer Res., October 15, 2004; 10(20): 6855 - 6864. [Abstract] [Full Text] [PDF]

				C Gasche, M C E Lomer, I Cavill, and G Weiss Iron, anaemia, and inflammatory bowel diseases Gut, August 1, 2004; 53(8): 1190 - 1197. [Abstract] [Full Text] [PDF]

				I. Bosaeus, P. Daneryd, and K. Lundholm Dietary Intake, Resting Energy Expenditure, Weight Loss and Survival in Cancer Patients J. Nutr., November 1, 2002; 132(11): 3465S - 3466. [Abstract] [Full Text] [PDF]

				D. P. Kotler Cachexia Ann Intern Med, October 17, 2000; 133(8): 622 - 634. [Abstract] [Full Text] [PDF]